𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An experimental model of tardive dyskinesia

✍ Scribed by H. L. Klawans; R. Rubovits

Publisher
Springer
Year
1972
Tongue
English
Weight
750 KB
Volume
33
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Tardive dyskinesia model in the common m
Tardive dyskinesia model in the common marmoset
✍ Rebecka Klintenberg; Lars Gunne; Per E. AndrΓ©n πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 58 KB

## Abstract Thirteen adult common marmosets (__Callithrix jacchus__) were given once‐monthly injections of haloperidol decanoate (5–15 mg/kg i.m.) for one year. Thereafter, drug‐free and treatment periods alternated at 3‐month intervals. After 2.5 to 14 months, 12 monkeys showed symptoms of tardive

Metoclopramide-induced tardive dyskinesi
Metoclopramide-induced tardive dyskinesia in an infant
✍ Nicte I. Mejia; Joseph Jankovic πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 63 KB πŸ‘ 1 views

## Abstract We describe a 1‐year‐old girl who developed orofaciolingual stereotypy at age 2 months after a 17‐day treatment with metoclopramide for gastroesophageal reflux. The stereotypy, documented by sequential videos, persisted for at least 9 months after the drug was discontinued. This patient

Cholinergic suppression of tardive dyski
Cholinergic suppression of tardive dyskinesia
✍ W. E. Fann; C. R. Lake; C. J. Gerber; G. M. McKenzie πŸ“‚ Article πŸ“… 1974 πŸ› Springer 🌐 English βš– 408 KB

Tardive dyskinesia (TD), a hyperkinetic disorder associated with long-term neuroleptic treatment, may be a manifestation of imbalance of opposing DA and ACh dependent systems in the CNS (i.e., hyperdopamine activity or hypoeholinergic function). Dopamine blocking agents give some transient relief of

Levetiracetam in tardive dyskinesia: An
Levetiracetam in tardive dyskinesia: An open label study
✍ Spiros Konitsiotis; Sofia Pappa; Christos Mantas; Venos Mavreas πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 53 KB πŸ‘ 2 views

Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia we